In the event the medication is discontinued soon after attaining fat reduction, a possibility of rebound bodyweight gain exists. This was demonstrated within an extension of your Stage one trial, where by individuals, just after discontinuing weekly subcutaneous semaglutide 2.This randomized medical demo examines the influence of tirzepatide on the